Phio Pharmaceuticals Corp (PHIO)

Currency in USD
1.650
+0.430(+35.25%)
Closed·
1.620-0.030(-1.82%)
·
Unusual trading volume
PHIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.2171.880
52 wk Range
0.8134.190
Key Statistics
Prev. Close
1.22
Open
1.22
Day's Range
1.217-1.88
52 wk Range
0.813-4.19
Volume
24.2M
Average Volume (3m)
3.59M
1-Year Change
-8.8398%
Book Value / Share
1.72
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PHIO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.000
Upside
+748.48%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Phio Pharmaceuticals Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Phio Pharmaceuticals Corp Company Profile

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

Compare PHIO to Peers and Sector

Metrics to compare
PHIO
Peers
Sector
Relationship
P/E Ratio
−2.2x−3.1x−0.5x
PEG Ratio
−0.030.100.00
Price/Book
1.8x4.2x2.6x
Price / LTM Sales
-112.1x3.3x
Upside (Analyst Target)
-175.7%47.0%
Fair Value Upside
Unlock0.4%6.1%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 14.000
(+748.48% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy14.00+748.48%-MaintainJun 26, 2025
H.C. Wainwright
Buy14.00+748.48%-New CoverageJun 05, 2025
H.C. Wainwright
Buy4.00+142.42%-MaintainApr 08, 2025
H.C. Wainwright
Buy4.00+142.42%-MaintainFeb 20, 2025

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
-0.44 / -0.40
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PHIO Income Statement

People Also Watch

2.8300
FEED
-0.35%
5.7100
MNTS
+5.35%
1.3300
HURA
-4.32%
1.500
ICON
+4.17%

FAQ

What Is the Phio Pharma (PHIO) Stock Price Today?

The Phio Pharma stock price today is 1.650

What Stock Exchange Does Phio Pharma Trade On?

Phio Pharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Phio Pharma?

The stock symbol for Phio Pharma is "PHIO."

What Is the Phio Pharma Market Cap?

As of today, Phio Pharma market cap is 17.760M.

What Is Phio Pharma's Earnings Per Share (TTM)?

The Phio Pharma EPS (TTM) is -2.02.

From a Technical Analysis Perspective, Is PHIO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Phio Pharma Stock Split?

Phio Pharma has split 6 times.

How Many Employees Does Phio Pharma Have?

Phio Pharma has 5 employees.

What is the current trading status of Phio Pharma (PHIO)?

As of Feb 15, 2026, Phio Pharma (PHIO) is trading at a price of 1.650, with a previous close of 1.220. The stock has fluctuated within a day range of 1.217 to 1.880, while its 52-week range spans from 0.813 to 4.190.

What Is Phio Pharma (PHIO) Price Target According to Analysts?

The average 12-month price target for Phio Pharma is USD14.000, with a high estimate of USD14 and a low estimate of USD14. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +748.48% Upside potential.

What Is the PHIO After Hours Price?

PHIO's last after hours stock price is 1.620, the stock has decreased by -0.030, or -1.820%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.